A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS REM-422
Verified

What's the purpose of this trial?

In this study, researchers want to find the best dose of REM-422 to treat leukemia or myelodysplastic syndrome (MDS). The people in this study have acute myeloid leukemia (AML) or higher-risk MDS that keeps growing even with treatment. Higher-risk means the disease has a high chance of coming back or not responding to therapy.

REM-422 reduces the amount of the MYB protein, which promotes cancer cell growth. REM-422 is taken orally (by mouth).

This trial is currently open and accepting patients.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

To join this study, there are a few conditions. You must:

  • Have AML or higher-risk MDS that came back or keeps growing after treatment.
  • Have completed prior treatment at least 2 weeks before taking REM-422.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.

Additional Trial Information

Phase 1

Enrollment: 100 patients (estimated)

View More
Need Help?

Interested in joining or learning more about this trial?

(888) 828-2206

Trial Links

Read the latest news and updates on this trial.

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

California

City of Hope Comprehensive Cancer Center Beckman Research Institute

Duarte, CA

Open and Accepting

Florida

Moffitt Cancer Center Magnolia Campus

Tampa, FL

Open and Accepting

Massachusetts

Massachusetts General Hospital

Boston, MA

Open and Accepting

New York

Memorial Sloan Kettering Cancer Center

New York, NY

Recruitment on Hold

Texas

MD Anderson Cancer Center The University of Texas

Houston, TX

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • Add this trial to your favorites keyboard_arrow_right

    If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

Learn more about how we work with trial sponsors